{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:21:22Z","timestamp":1793578882264,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This study was fully funded by Novartis Pharma AG. Erenumab is co-developed in partnership with Amgen and Novartis"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstact<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>DRAGON was a phase 3, randomised, double-blind, placebo-controlled study which evaluated the efficacy and safety of erenumab in patients with chronic migraine (CM) from Asia not adequately represented in the global pivotal CM study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>DRAGON study was conducted across 9 Asian countries or regions including mainland China, India, the Republic of Korea, Malaysia, the Philippines, Singapore, Taiwan, Thailand, and Vietnam. Patients (<jats:italic>N<\/jats:italic>\u2009=\u2009557) with CM (aged 18\u201365\u00a0years) were randomised (1:1) to receive once-monthly subcutaneous erenumab 70\u00a0mg or matching placebo for 12\u00a0weeks. The primary endpoint was the change in monthly migraine days (MMD) from baseline to the last 4\u00a0weeks of the 12-week double-blind treatment phase (DBTP). Secondary endpoints included achievement of\u2009\u2265\u200950% reduction in MMD, change in monthly acute headache medication days, modified migraine disability assessment (mMIDAS), and safety. Study was powered for the primary endpoint of change from baseline in MMD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At baseline, the mean (SD) age was 41.7 (\u00b1\u200910.9) years, and 81.5% (n\u2009=\u2009454) patients were women. The mean migraine duration was 18.0 (\u00b1\u200911.6) years, and the mean MMD was 19.2 (\u00b1\u20095.4). 97.8% (n\u2009=\u2009545) randomised patients completed the DBTP. Overall, demographics and baseline characteristics were balanced between the erenumab and placebo groups except for a slightly higher proportion of women in the placebo group. At Week 12, the adjusted mean change from baseline in MMD was\u2009\u2212\u20098.2\u00a0days for erenumab and\u2009\u2212\u20096.6\u00a0days for placebo, with a statistically significant difference for erenumab versus placebo (adjusted mean difference vs placebo:\u2009\u2212\u20091.57 [95%CI:\u2009\u2212\u20092.83,\u2009\u2212\u20090.30]; <jats:italic>P<\/jats:italic>\u2009=\u20090.015). A greater proportion of patients treated with erenumab achieved\u2009\u2265\u200950% reduction in MMD versus placebo (47.0% vs 36.7%, <jats:italic>P<\/jats:italic>\u2009=\u20090.014). At Week 12, greater reductions in monthly acute headache medication days (\u2212\u20095.34 vs\u2009\u2212\u20094.66) and mMIDAS scores (\u2212\u200914.67 vs\u2009\u2212\u200912.93) were observed in patients treated with erenumab versus placebo. Safety and tolerability profile of erenumab was comparable to placebo, except the incidence of constipation (8.6% for erenumab vs 3.2% for placebo).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>DRAGON study demonstrated the efficacy and safety of erenumab 70\u00a0mg in patients with CM from Asia. No new safety signals were observed during the DBTP compared with the previous trials.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03867201\">NCT03867201<\/jats:ext-link><\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-022-01514-9","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T02:02:47Z","timestamp":1668996167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8933-088X","authenticated-orcid":false,"given":"Shengyuan","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1053-4682","authenticated-orcid":false,"given":"Byung-Kun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0598-5772","authenticated-orcid":false,"given":"Hebo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6302-8332","authenticated-orcid":false,"given":"Jiying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6124-2917","authenticated-orcid":false,"given":"Tingmin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0422-9078","authenticated-orcid":false,"given":"Yajun","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6090-6344","authenticated-orcid":false,"given":"Michal","family":"Arkuszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Ecochard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihua","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1410-5615","authenticated-orcid":false,"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5179-5358","authenticated-orcid":false,"given":"Shuu-Jiun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"key":"1514_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"BD 2016 Headache Collaborators","year":"2018","unstructured":"BD 2016 Headache Collaborators (2018) Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17:954\u2013976","journal-title":"Lancet Neurol"},{"key":"1514_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"GBD 2016 Neurology Collaborators","year":"2019","unstructured":"GBD 2016 Neurology Collaborators (2019) Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18:459\u2013480","journal-title":"Lancet Neurol"},{"key":"1514_CR3","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1097\/j.pain.0000000000002275","volume":"163","author":"S Safiri","year":"2022","unstructured":"Safiri S, Pourfathi H, Eagan A et al (2022) Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain 163:e293\u2013e309","journal-title":"Pain"},{"key":"1514_CR4","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.1526-4610.2007.01004.x","volume":"48","author":"JL Brandes","year":"2008","unstructured":"Brandes JL (2008) The migraine cycle: patient burden of migraine during and between migraine attacks. Headache 48:430\u2013441","journal-title":"Headache"},{"key":"1514_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s10194-019-0993-0","volume":"20","author":"M Leonardi","year":"2019","unstructured":"Leonardi M, Raggi A (2019) A narrative review on the burden of migraine: when the burden is the impact on people\u2019s life. J Headache Pain 20:41","journal-title":"J Headache Pain"},{"key":"1514_CR6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/0333102410381145","volume":"31","author":"AM Blumenfeld","year":"2011","unstructured":"Blumenfeld AM, Varon SF, Wilcox TK et al (2011) Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 31:301\u2013315","journal-title":"Cephalalgia"},{"key":"1514_CR7","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1177\/0333102420919098","volume":"40","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Evers S (2020) International Classification of Headache Disorders - ICHD-4 alpha. Cephalalgia 40:887\u2013888","journal-title":"Cephalalgia"},{"key":"1514_CR8","first-page":"1","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders\u00a03rd edition. Cephalalgia 38:1\u2013211","journal-title":"Cephalalgia"},{"key":"1514_CR9","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/head.14154","volume":"61","author":"R Ishii","year":"2021","unstructured":"Ishii R, Schwedt TJ, Dumkrieger G et al (2021) Chronic versus episodic migraine: The 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. Headache 61:992\u20131003","journal-title":"Headache"},{"key":"1514_CR10","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","volume":"53","author":"AM Blumenfeld","year":"2013","unstructured":"Blumenfeld AM, Bloudek LM, Becker WJ et al (2013) Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache 53:644\u2013655","journal-title":"Headache"},{"key":"1514_CR11","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Dodick DW, Varon SF et al (2014) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 35:478\u2013488","journal-title":"Cephalalgia"},{"key":"1514_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.18553\/jmcp.2014.20.1.22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF (2014) Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 20:22\u201333","journal-title":"J Manag Care Pharm"},{"key":"1514_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s10194-019-1062-4","volume":"20","author":"T Takeshima","year":"2019","unstructured":"Takeshima T, Wan Q, Zhang Y et al (2019) Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature. J Headache Pain 20:111","journal-title":"J Headache Pain"},{"key":"1514_CR14","first-page":"62938","volume":"2015","author":"R Gooriah","year":"2015","unstructured":"Gooriah R, Nimeri R, Ahmed F (2015) Evidence-based treatments for adults with migraine. Pain Res Treat 2015:62938","journal-title":"Pain Res Treat"},{"key":"1514_CR15","first-page":"721","volume":"22","author":"Chinese Medical Association Group","year":"2016","unstructured":"Chinese Medical Association Group (2016) Guide to the prevention and treatment of migraine in China [Chinese]. Chin J Pain Med 22:721\u2013727","journal-title":"Chin J Pain Med"},{"key":"1514_CR16","first-page":"33","volume":"26","author":"TC Huang","year":"2017","unstructured":"Huang TC, Lai TH, Treatment guideline subcommittee of Taiwan headache society Taiwan headache society, et al (2017) Medical treatment guidelines for preventive treatment of migraine. Acta Neurologica Taiwanica 26:33\u201353","journal-title":"Acta Neurologica Taiwanica"},{"key":"1514_CR17","doi-asserted-by":"publisher","first-page":"100","DOI":"10.17340\/jkna.2020.2.3","volume":"38","author":"H-S Moon","year":"2020","unstructured":"Moon H-S, Park K-Y, Chung J-M et al (2020) An update on migraine treatment [Korean]. J Korean Neurol Assoc 38:100\u2013110","journal-title":"J Korean Neurol Assoc"},{"issue":"10","key":"1514_CR18","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00228-014-1729-3","volume":"70","author":"H Wu","year":"2014","unstructured":"Wu H, Wu G (2014) Strategy to address innovative off-label medication use in China: grading management. Eur J Clin Pharmacol 70(10):1271\u20131273","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1514_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/head.12997","volume":"57","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD (2017) Topiramate in migraine prevention: a 2016 perspective. Headache 57(1):165\u2013178","journal-title":"Headache"},{"key":"1514_CR20","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1177\/03331024211024153","volume":"41","author":"A Roxas","year":"2021","unstructured":"Roxas A, Quiles LE, Wang S-J (2021) Delivery of care for migraine in the Asian Oceanian region: a cross-sectional study. Cephalalgia 41:1348\u20131358","journal-title":"Cephalalgia"},{"key":"1514_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s10194-020-01117-2","volume":"21","author":"S Yu","year":"2020","unstructured":"Yu S, Zhang Y, Yao Y et al (2020) Migraine treatment and healthcare costs: retrospective analysis of the China Health Insurance Research Association (CHIRA) database. J Headache Pain 21:53","journal-title":"J Headache Pain"},{"key":"1514_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/head.13302","volume":"58","author":"U Reuter","year":"2018","unstructured":"Reuter U (2018) A review of monoclonal antibody therapies and other preventative treatments in migraine. Headache 58:48\u201359","journal-title":"Headache"},{"key":"1514_CR23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s10194-021-01335-2","volume":"22","author":"F Vandervorst","year":"2021","unstructured":"Vandervorst F, Van Deun L, Van Dycke A et al (2021) CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain 22:128","journal-title":"J Headache Pain"},{"key":"1514_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1124\/jpet.115.227793","volume":"356","author":"L Shi","year":"2016","unstructured":"Shi L, Lehto SG, Zhu DX et al (2016) Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther 356:223\u2013231","journal-title":"J Pharmacol Exp Ther"},{"key":"1514_CR25","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(16)00019-3","volume":"15","author":"H Sun","year":"2016","unstructured":"Sun H, Dodick DW, Silberstein S et al (2016) Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15:382\u2013390","journal-title":"Lancet Neurol"},{"key":"1514_CR26","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y et al (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377:2123\u20132132","journal-title":"N Engl J Med"},{"key":"1514_CR27","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL et al (2018) ARISE: A phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38:1026\u20131037","journal-title":"Cephalalgia"},{"key":"1514_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16:425\u2013434","journal-title":"Lancet Neurol"},{"key":"1514_CR29","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1111\/head.13652","volume":"59","author":"F Sakai","year":"2019","unstructured":"Sakai F, Takeshima T, Tatsuoka Y et al (2019) A randomized phase 2 study of erenumab for the prevention of episodic migraine in Japanese adults. Headache 59:1731\u20131742","journal-title":"Headache"},{"key":"1514_CR30","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1177\/03331024211024160","volume":"41","author":"S-J Wang","year":"2021","unstructured":"Wang S-J, Roxas AA, Saravia B et al (2021) Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study. Cephalalgia 41:1285\u20131297","journal-title":"Cephalalgia"},{"key":"1514_CR31","unstructured":"Aimovig\u2122 United States prescribing information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761077s009lbl.pdf. Accessed 10 May,\u00a02022"},{"key":"1514_CR32","unstructured":"Aimovig\u2122 Summary of product characteristics: Available at: https:\/\/www.ema.europa.eu\/documents\/product-information\/aimovig-epar-product-information_en.pdf. Accessed 10 May, 2022"},{"key":"1514_CR33","unstructured":"Novartis Press release. Novartis marks a new era for migraine patients with the EU approval of Aimovig\u00ae, a first-of-its-kind treatment specifically designed for migraine prevention. Available at: https:\/\/www.novartis.com\/news\/media-releases\/novartis-marks-new-era-migraine-patients-eu-approval-aimovig-first-its-kind-treatment-specifically-designed-migraine-prevention. Accessed 10 May, 2022"},{"key":"1514_CR34","unstructured":"Amgen. Amgen announces approval of Aimovig\u00ae (Erenumab) in Japan for the suppression of onset of migraine attacks in adults. Available at: https:\/\/www.amgen.com\/newsroom\/press-releases\/2021\/06\/amgen-announces-approval-of-aimovig-erenumab-in-japan-for-the-suppression-of-onset-of-migraine-attacks-in-adults. Accessed 10 May, 2022"},{"key":"1514_CR35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1526-4610.2009.01481.x","volume":"50","author":"SD Silberstein","year":"2010","unstructured":"Silberstein SD, Marmura MJ, Shaw J et al (2010) Headache prophylaxis with BoNTA: patient characteristics. Headache 50:63\u201370","journal-title":"Headache"},{"key":"1514_CR36","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jpain.2014.11.004","volume":"16","author":"DW Dodick","year":"2015","unstructured":"Dodick DW, Turkel CC, DeGryse RE et al (2015) Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example. J Pain 16:164\u2013175","journal-title":"J Pain"},{"key":"1514_CR37","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1111\/head.13907","volume":"60","author":"RB Forbes","year":"2020","unstructured":"Forbes RB, McCarron M, Cardwell CR (2020) Efficacy and contextual (placebo) effects of CGRP antibodies for migraine: systematic review and meta-analysis. Headache 60:1542\u20131557","journal-title":"Headache"},{"key":"1514_CR38","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/IBPC.S152761","volume":"11","author":"MR Pioli","year":"2018","unstructured":"Pioli MR, Ritter AM, de Faria AP et al (2018) White coat syndrome and its variations: differences and clinical impact. Integr Blood Press Control 11:73\u201379","journal-title":"Integr Blood Press Control"},{"key":"1514_CR39","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1046\/j.1468-2982.2000.00085.x","volume":"20","author":"SJ Wang","year":"2000","unstructured":"Wang SJ, Fuh JL, Young YH et al (2000) Prevalence of migraine in Taipei, Taiwan: a population-based survey. Cephalalgia 20:566\u2013572","journal-title":"Cephalalgia"},{"key":"1514_CR40","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41598-021-04250-3","volume":"12","author":"KM Kim","year":"2022","unstructured":"Kim KM, Kim BK, Lee W et al (2022) Prevalence and impact of visual aura in migraine and probable migraine: a population study. Sci Rep 12:426","journal-title":"Sci Rep"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01514-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01514-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01514-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T02:02:55Z","timestamp":1668996175000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01514-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,21]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1514"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01514-9","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,21]]},"assertion":[{"value":"8 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol, protocol amendments, the informed consent forms, and accompanying materials were reviewed and approved by the Institutional Review Board (IRBs)\/Independent Ethics Committee (IECs) and Health Authorities at each study centre.All participants provided written informed consent before undergoing any study-specific procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was received.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Shengyuan Yu, Hebo Wang, Jiying Zhou, Qi Wan, Tingmin Yu, and Yajun Lian declare that there is no conflict of interest.Shuu-Jiun Wang has received personal compensation for serving on a Scientific Advisory board for Eli-Lilly and Novartis. He has received personal compensation for serving on as a speaker or moderator for AbbVie, Biogen, Eisai and Pfizer, Taiwan. The institution of Prof. Wang has received research support from Brain Research Center, National Yang-Ming University from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan, Eli-Lilly and Novartis.Byung-Kun Kim has received personal compensation for serving on a Scientific Advisory board for Lundbeck Korea and Novartis. He has received personal compensation for serving on as a speaker or moderator for Allergan Korea, Lilly Korea, Teva Korea, GSK Korea, Lundbeck Korea and SK pharm.Michal Arkuszewski, Laurent Ecochard, Shihua Wen, and Wendy Su are employees of and hold stocks in Novartis.Fangfang Yin and Zheng Li are employees of China Novartis Institutes for Biomedical Research Co Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"146"}}